Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) from Overweight to Overweight.
Cantor Fitzgerald Reiterates Overweight on Kura Oncologyto Overweight
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.